# South Korea Neuropsychiatric Disorders Treatment Market > South Korea Neuropsychiatric Disorders Treatment Market Research Report By Type (Degenerative Diseases, Neurotic Disorders, Psychosis, Others), By Application (Shock Treatment, Drug Treatment, Others) and By End User (Hospitals, Clinics, Research Centre’s, Others) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 10.19% - **2024:** $ 3,630 Million - **2025:** $ 3,999.9 Million - **2035:** $ 10,550 Million - **Key Players:** Johnson & Johnson (US), Pfizer (US), Eli Lilly and Company (US), AstraZeneca (GB), Bristol-Myers Squibb (US), Novartis (CH), Sanofi (FR), Roche (CH), Otsuka Pharmaceutical (JP) **Report ID:** MRFR/HC/43512-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/south-korea-neuropsychiatric-disorders-treatment-market-45192 --- ## Market Summary ## **South Korea Neuropsychiatric Disorders Treatment Market Overview** As per MRFR analysis, the South Korea Neuropsychiatric Disorders Treatment Market Size was estimated at 3.29 (USD Billion) in 2023.The South Korea Neuropsychiatric Disorders Treatment Market Industry is expected to grow from 3.63(USD Billion) in 2024 to 10.11 (USD Billion) by 2035. The South Korea Neuropsychiatric Disorders Treatment Market CAGR (growth rate) is expected to be around 9.773% during the forecast period (2025 - 2035) **Key South Korea Neuropsychiatric Disorders Treatment Market Trends Highlighted** Various factors are shaping notable trends in the South Korea Neuropsychiatric Disorders Treatment Market. An increase in the awareness of mental health problems alongside ongoing changes in societal attitudes on help-seeking behavior towards neuropsychiatric disorders is mitigating market growth. The South Korean government has been executing mental health policies, offering special attention on premature intervention and focus in the area. Furthermore, there has been an increase in the number of specialized treatment centers and the availability of telemedicine, resulting in improved access to therapy. This coincides with the increase in the use of technology in healthcare, also referred to as digital health, which has gained traction in South Korea. As more personalized and novel treatment methods are sought after, these markets tend to have more opportunities available. There is a growing movement to develop drugs for treatment of neuropsychiatric disorders for depression, anxiety, schizophrenia, and other ailments and it is anticipated that many research institutions will start collaborating with drug companies to develop new therapies. In addition, there is already an established interest in wellness programs and other more holistic approaches that are integrative, like mindfulness and cognitive behavioral therapy, which compliment conventional treatments. This creates a chance to apply both clinical and non-clinical approaches to improve patients' health. Recent patterns have also indicated an increase in the integration of public and private funding for the treatment of neuropsychiatric disorders. As part of mental health strategies, there is an increased focus on enhancing the infrastructure of the mental health care system as well as the technology associated with it. In addition, due to the increase in the elderly population, there is a greater need for effective interventions for age-related neuropsychiatric disorders, which has spurred innovation in research and development. Therefore, the South Korea Neuropsychiatric Disorders Treatment Market is shifting in response to the demographic changes and showing their responsiveness in the provision of mental health services. **South Korea Neuropsychiatric Disorders Treatment Market Drivers** **Growing Prevalence of Neuropsychiatric Disorders** The South Korea Neuropsychiatric Disorders Treatment Market is driven by the rising prevalence of neuropsychiatric disorders such as depression, anxiety, and bipolar disorder. Recent statistics indicate that approximately 31.3% of South Korean adults experience some form of mental health issue during their lifetime. This alarming rate is underscored by a report from the Korean Ministry of Health and Welfare which revealed a 21% increase in mental health diagnoses from 2019 to 2022.The government has recognized this growing health crisis and is advocating for improved mental health policies and funding for treatment options. As established organizations, such as the Korean Neuropsychiatric Association, work towards awareness and education, the necessity for effective treatment solutions in this expanding market continues to grow, reflecting a significant opportunity for stakeholders involved in the South Korea Neuropsychiatric Disorders Treatment Market Industry. **Government Initiatives and Funding** The South Korean government is increasingly prioritizing mental health through various initiatives and funding programs aimed at improving treatment accessibility. In 2021, the government allocated a budget of over 1 trillion won towards mental health services, reflecting a substantial commitment to addressing the rising demand for neuropsychiatric disorder treatments. This comprehensive approach not only facilitates access to better healthcare services but also encourages research and development in the sector.Organizations like the Korean Psychiatric Association play a crucial role in advocating for policy enhancements and driving funding to ensure that innovations in treatment become available, positively impacting the South Korea Neuropsychiatric Disorders Treatment Market. **Rising Awareness and Reduced Stigma** There has been a notable shift in societal perceptions regarding mental health in South Korea, leading to increased awareness and a subsequent decline in stigma associated with seeking treatment. Initiatives led by both governmental bodies and non-profit organizations aim to promote mental health literacy among the population. Statistics reveal that about 65% of South Koreans are now more willing to discuss mental health issues publicly compared to five years ago.This transformation in attitudes is propelling a more significant number of individuals to seek treatment, thus fueling growth in the South Korea Neuropsychiatric Disorders Treatment Market Industry. The engagement of community organizations in these awareness campaigns is critical in shaping a supportive environment for those affected. **South Korea Neuropsychiatric Disorders Treatment Market Segment Insights** **Neuropsychiatric Disorders Treatment Market Type Insights** The South Korea Neuropsychiatric Disorders Treatment Market presents a multifaceted landscape, primarily segmented by Type, which encompasses Degenerative Diseases, Neurotic Disorders, Psychosis, and Others. The rising prevalence of mental health issues in South Korea has significantly influenced the market dynamics, contributing to an overall increase in demand for effective treatment options and solutions. Among these segments, degenerative diseases, such as Alzheimer’s and Parkinson’s, hold substantial importance due to the aging population, which has led to an increased incidence of cognitive disorders. The country’s commitment to improving elderly care and mental health services showcases the growing acknowledgment of these challenges. In contrast, neurotic disorders, which include anxiety and depression, have emerged as a critical focus due to their high prevalence among younger demographics. The South Korean government has implemented various mental health initiatives and community programs aimed at decreasing the stigma associated with these disorders, further driving demand for effective therapeutic interventions. Psychosis, characterized by altered perceptions of reality, continues to represent a significant challenge to healthcare providers, necessitating advanced treatment strategies to address both pharmacological and psychotherapeutic needs. The increasing awareness of mental health alongside educational programs further emphasizes the significance of addressing this segment of the population. Moreover, the 'Others' category captures various fewer common disorders that still demand attention and treatment, ensuring that diverse needs within the population are met. Overall, the South Korea Neuropsychiatric Disorders Treatment Market segmentation reflects a growing recognition of the complexities involved in treating diverse mental health conditions, coupled with a commitment from governmental and healthcare entities to enhance the quality of care provided to patients. This focused approach is expected to foster innovation in treatment methodologies and contribute positively to the South Korea Neuropsychiatric Disorders Treatment Market revenue trajectory in the years ahead. **Neuropsychiatric Disorders Treatment Market Application Insights** The South Korea Neuropsychiatric Disorders Treatment Market is characterized by its diverse application spectrum, addressing various treatment modalities for neuropsychiatric conditions. Within this market, Shock Treatment and Drug Treatment are pivotal, with Shock Treatment being recognized for its efficacy in severe cases, often where traditional therapies have proven less effective. Drug Treatment, on the other hand, remains a critical option, with a broad range of pharmacological solutions targeting different disorders, significantly bolstered by ongoing research and development in the field.The others category encompasses alternative approaches and emerging therapies, highlighting the market's responsiveness to innovations and patient needs. As South Korea places a strong emphasis on mental health awareness and the integration of modern treatment methodologies, the overall dynamics of the South Korea Neuropsychiatric Disorders Treatment Market reflect the changing landscape of mental health care, aligning with growing public health initiatives and increasing government support for mental health programs. This changing environment offers substantial opportunities for growth, particularly as societal acceptance and recognition of these disorders continue to advance. **Neuropsychiatric Disorders Treatment Market End User Insights** The End User segment of the South Korea Neuropsychiatric Disorders Treatment Market is diverse and plays a crucial role in the effective management of mental health issues. Hospitals represent a critical component, providing acute and long-term care for individuals with severe neuropsychiatric conditions, ensuring comprehensive treatment in a well-equipped environment. Clinics, on the other hand, cater to outpatient services, allowing for ongoing management and therapy for patients seeking psychiatric care and support. Research centers contribute significantly by advancing the understanding of neuropsychiatric disorders through clinical studies and innovation, driving the development of more effective treatment modalities. Additionally, the "Others" category encompasses a variety of alternative care platforms, such as community services and online mental health platforms, reflecting a growing trend toward accessible and integrated care solutions. Collectively, these end users reflect a commitment to enhancing patient outcomes in South Korea, as the importance of mental health awareness rises in alignment with national health policies focusing on comprehensive psychiatric support. The South Korea Neuropsychiatric Disorders Treatment Market is likely to see substantial growth as demand for these services increases, fueled by growing awareness, changing societal attitudes towards mental health, and government initiatives aimed at improving mental healthcare access. **South Korea Neuropsychiatric Disorders Treatment Market Key Players and Competitive Insights** The South Korea Neuropsychiatric Disorders Treatment Market is characterized by a dynamic and competitive landscape where various pharmaceutical companies are relentlessly developing and commercializing innovative therapies to address a wide array of mental health disorders. With increasing awareness regarding mental health and the growing prevalence of conditions such as depression, anxiety, and schizophrenia, the market has garnered significant attention from both investors and healthcare providers. The competitive analysis within this sector reveals a focus on research and development, collaboration with healthcare institutions, and engaging in continuous clinical trials to enhance the efficacy and safety profiles of new psychiatric medications. Companies are striving to position themselves effectively amid stringent regulatory frameworks, diverse patient needs, and advancing technological solutions in treatment approaches, thus creating a robust competitive environment that fosters innovation.Soo)Gen Inc. holds a significant position in the South Korea Neuropsychiatric Disorders Treatment Market, renowned for its commitment to the research and development of groundbreaking therapies targeting neuropsychiatric conditions. The company has developed a portfolio of products that are aimed at addressing unmet medical needs within the psychiatric domain. Their strengths lie in their robust pipeline of drug candidates, which are undergoing various stages of clinical development, and their strategic collaborations with academic institutions and research organizations that enhance their innovation capabilities. Soo)Gen Inc. also emphasizes patient-centric approaches in its therapeutic strategies, focusing on improving patients' quality of life and therapeutic outcomes. By dedicated efforts in clinical research and engagement with the mental health community, Soo)Gen Inc. has established a credible presence in the neuropsychiatric treatment landscape of South Korea.Hanmi Pharmaceutical is another major player in the South Korean Neuropsychiatric Disorders Treatment Market, widely recognized for its comprehensive suite of products that address mental health challenges. The company has made significant strides in developing drugs that cater to various neuropsychiatric disorders, reflecting its strong commitment to mental health research. Hanmi Pharmaceutical possesses a solid market presence, bolstered by strategic mergers and acquisitions that have expanded their capabilities and resource access. Moreover, the company's strengths include its diverse portfolio of psychiatric medications that cater to a range of conditions, bolstered by significant investment in R&D to foster new product development. The firm has successfully formed partnerships with international stakeholders for collaborative studies and market expansions, further enhancing its competitive position within South Korea's mental health treatment domain. This proactive approach not only strengthens Hanmi Pharmaceutical's market presence but also enhances its reputation as a key contributor to innovations in neuropsychiatric treatment solutions. **Key Companies in the South Korea Neuropsychiatric Disorders Treatment Market Include** **South Korea Neuropsychiatric Disorders Treatment Market Industry Developments** The South Korea Neuropsychiatric Disorders Treatment Market has been witnessing significant developments recently. Key players such as Hanmi Pharmaceutical and SK Biopharmaceuticals have made strides in advancing drug pipelines to address psychiatric conditions. The market is currently experiencing an uptick in investment, with companies like Samsung Biologics focusing on biologics for conditions like schizophrenia and depression. In terms of mergers and acquisitions, LG Chem announced a partnership with a biotech firm in August 2023 to expand its portfolio in neuropsychiatric treatments, enhancing its R&D capabilities. Additionally, Daewoong Pharmaceutical has been actively investing in innovative therapies, reflecting a broader trend of increased spending in the neuropsychiatric sector. The government's support for mental health initiatives further contributes to market growth, promoting accessibility and research funding. Over the past two years, there has been a noticeable increase in public awareness and reduced stigma regarding mental health, driving demand for products and services in this domain. As the market evolves, ongoing collaborations among key industry players are expected to create new opportunities for growth and innovation in South Korea's neuropsychiatric treatment landscape. **South Korea Neuropsychiatric Disorders Treatment Market Segmentation Insights** ## Market Drivers ### Supportive Regulatory Environment A supportive regulatory environment is fostering growth in the neuropsychiatric disorders-treatment market. The South Korean government has implemented policies aimed at improving mental health services, including streamlined approval processes for new treatments and increased funding for mental health initiatives. These regulatory changes are designed to encourage innovation and facilitate access to care for patients. As a result, pharmaceutical companies are more likely to invest in the development of new therapies, knowing that there is a favorable framework for bringing these products to market. This supportive environment is expected to enhance the overall landscape of neuropsychiatric treatment options available to patients in South Korea. ### Advancements in Pharmaceutical Research Innovations in pharmaceutical research are significantly impacting the neuropsychiatric disorders-treatment market. The development of novel therapeutics, including targeted therapies and personalized medicine, is enhancing treatment efficacy for various neuropsychiatric conditions. For instance, recent breakthroughs in drug formulations have led to improved outcomes for patients with depression and anxiety disorders. The South Korean pharmaceutical industry is investing heavily in research and development, with expenditures reaching approximately $3 billion annually. This investment is expected to yield new treatment options that could transform the landscape of neuropsychiatric care. As these advancements become available, they are likely to attract more patients seeking effective solutions, thereby driving market growth. ### Increased Focus on Mental Health Awareness The growing emphasis on mental health awareness in South Korea is a pivotal factor influencing the neuropsychiatric disorders-treatment market. Public campaigns and educational initiatives are fostering a better understanding of mental health issues, reducing stigma, and encouraging individuals to seek treatment. This cultural shift is reflected in the rising number of consultations with mental health professionals, which has increased by approximately 30% over the past five years. As more people recognize the importance of mental well-being, the demand for neuropsychiatric treatments is expected to rise. This trend is likely to create new opportunities for healthcare providers and pharmaceutical companies within the market. ### Growing Prevalence of Mental Health Disorders The rising incidence of mental health disorders in South Korea is a critical driver for the neuropsychiatric disorders-treatment market. Recent studies indicate that approximately 1 in 5 individuals in South Korea experience some form of mental illness during their lifetime. This alarming statistic underscores the urgent need for effective treatment options. As awareness of mental health issues increases, more individuals are seeking help, thereby expanding the patient base for treatment providers. the neuropsychiatric disorders-treatment market is expected to see substantial growth as healthcare systems adapt to meet this demand.. Furthermore, the South Korean government has recognized the importance of mental health, leading to increased funding and resources allocated to mental health services. This could further stimulate market expansion.. ### Integration of Technology in Treatment Approaches the integration of technology into treatment approaches has reshaped the neuropsychiatric disorders-treatment market.. Digital health solutions, including mobile applications and online therapy platforms, are becoming increasingly popular among patients seeking convenient and accessible care. In South Korea, the use of teletherapy has surged, with reports indicating a 40% increase in usage over the past year. This technological advancement not only enhances patient engagement but also expands the reach of mental health services to underserved populations. As technology continues to evolve, it is expected to play a crucial role in the delivery of neuropsychiatric treatments, potentially leading to improved patient outcomes and market growth. ## Future Outlook The [Neuropsychiatric Disorders Treatment Market](https://www.marketresearchfuture.com/reports/neuropsychiatric-disorders-treatment-market-1281) is projected to grow at a 10.19% CAGR from 2025 to 2035, driven by increasing prevalence and advancements in treatment options. **New opportunities:** - Development of telehealth platforms for remote patient monitoring - Investment in AI-driven diagnostic tools for early detection - Expansion of personalized medicine approaches in treatment protocols By 2035, the market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Disorders: Degenerative Diseases (Largest) vs. Neurotic Disorders (Fastest-Growing) In the South Korea neuropsychiatric disorders-treatment market, the distribution of market share among the disorder segments shows that Degenerative Diseases hold the largest share, attracting significant attention from both healthcare providers and patients. Meanwhile, Neurotic Disorders exhibit a rapidly growing market share as awareness and diagnosis rates improve, indicating a shift in focus towards mental health interventions. The growth trends in the segment indicate a strong push towards innovative treatment options and increased research funding for Neurotic Disorders, which are becoming increasingly recognized. Factors such as rising stress levels, urbanization, and lifestyle changes have contributed to the uptick in patients seeking treatment for these conditions, making it one of the most dynamic segments within the market. Degenerative Diseases (Dominant) vs. Neurotic Disorders (Emerging) Degenerative Diseases represent a dominant force in the South Korea neuropsychiatric disorders-treatment market, characterized by progressive conditions that significantly impact patients' quality of life. This segment includes conditions such as Alzheimer's and Parkinson's, where the focus is on long-term management and supportive therapies. In contrast, Neurotic Disorders are emerging as a vital segment, spurred by increasing recognition of mental health issues. This category encompasses a range of anxiety and mood disorders, leading to greater patient engagement and demand for effective treatments. As the healthcare landscape evolves, both segments are adapting to new therapeutic advancements, catering to the nuanced needs of patients. ### By Treatment: Drug Treatment (Largest) vs. Shock Treatment (Fastest-Growing) In the South Korea neuropsychiatric disorders-treatment market, the treatment methods are diverse, but drug treatment emerges as the largest segment. It holds a significant share due to its widespread acceptance and effectiveness in managing various neuropsychiatric disorders. Meanwhile, shock treatment, although representing a smaller portion of the market, is gaining attention and showing considerable growth, driven by advancements in techniques and an increase in acceptance among healthcare professionals. The growth trends within this segment indicate a shift towards more innovative treatment approaches. The increasing recognition of mental health awareness among the public is a key driver for drug treatment. On the other hand, the rising efficacy of shock treatment coupled with new research supporting its benefits contributes to its status as the fastest-growing segment. Healthcare providers are exploring these methods to enhance treatment outcomes and patient safety. Drug Treatment: Dominant vs. Shock Treatment: Emerging Drug treatment is characterized by its established protocols and a broad range of medications available, catering to various neuropsychiatric disorders. As the dominant method in the South Korea neuropsychiatric disorders-treatment market, it benefits from extensive clinical support and ongoing research into new therapeutic options. Conversely, shock treatment is emerging as a viable alternative, increasingly recognized for its effectiveness, especially in severe cases. This method is evolving with technological advancements, including more refined techniques that reduce side effects and improve patient compliance. As awareness grows around mental health issues, both segments are expected to contribute significantly, balancing traditional and innovative treatment methodologies. ### By End User: Hospitals (Largest) vs. Clinics (Fastest-Growing) The South Korea neuropsychiatric disorders-treatment market is characterized by a diverse distribution of end users across various segments. Hospitals hold the largest market share, attributed to their extensive facilities and specialized staff equipped to handle complex neuropsychiatric cases. In contrast, clinics are emerging rapidly, appealing to patients who prefer outpatient care and personalized treatment, which contributes to their growing share in the market. Recent trends show an increasing inclination toward mental health awareness and the destigmatization of treatment, driving growth in both hospitals and clinics. The rise in outpatient services is further accelerated by technological advancements in treatment methodologies and an increase in the elderly population, which requires ongoing psychiatric services. Research centres also play a critical role in advancing treatment options and fostering partnerships with hospitals and clinics, ensuring a holistic approach to patient care. Hospitals: Dominant vs. Clinics: Emerging Hospitals are the dominant players in the South Korea neuropsychiatric disorders-treatment market, primarily due to their comprehensive infrastructure and resources. They offer a wide range of services and access to specialized professionals, making them the preferred choice for complicated cases that require in-depth intervention. On the other hand, clinics are emerging as an appealing alternative, primarily due to their focus on outpatient treatment and accessibility. They cater to a growing segment of patients seeking convenient, less invasive care options. The accessibility of clinics encourages regular follow-ups and treatment adherence, making them crucial for ongoing patient management. As the market evolves, collaboration between hospitals and clinics may enhance treatment pathways, optimizing patient outcomes and satisfaction. ## Competitive Benchmarking The neuropsychiatric disorders-treatment market in South Korea is characterized by a dynamic competitive landscape, driven by increasing prevalence rates of mental health conditions and a growing emphasis on innovative treatment modalities. Major players such as Johnson & Johnson (US), Pfizer (US), and Eli Lilly and Company (US) are strategically positioned to leverage their extensive research and development capabilities. These companies focus on innovation and partnerships to enhance their product offerings, thereby shaping a competitive environment that is increasingly reliant on advanced therapeutic solutions and patient-centric approaches.Key business tactics employed by these companies include localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market appears moderately fragmented, with a mix of established multinational corporations and emerging local players. This structure allows for a diverse range of treatment options, although the influence of key players remains substantial, as they often set the standards for innovation and quality in the sector. In September Johnson & Johnson (US) announced a collaboration with a South Korean biotech firm to develop a novel treatment for depression, which underscores the company's commitment to expanding its portfolio in the neuropsychiatric domain. This strategic move not only enhances J&J's research capabilities but also positions it to tap into local expertise, potentially accelerating the development of effective therapies tailored to the South Korean market. In August Pfizer (US) launched a new digital health platform aimed at improving patient engagement and adherence to treatment regimens for anxiety disorders. This initiative reflects Pfizer's focus on integrating technology into its therapeutic offerings, which may enhance patient outcomes and foster loyalty in a competitive market. The platform's success could serve as a model for future digital health initiatives across the industry. In October Eli Lilly and Company (US) expanded its clinical trial program for a new antipsychotic medication, aiming to address treatment-resistant schizophrenia. This expansion indicates Lilly's proactive approach to addressing unmet medical needs and highlights its commitment to innovation in neuropsychiatric treatments. The outcomes of these trials could significantly influence the company's market position and contribute to its growth trajectory in the coming years. As of November current trends in the neuropsychiatric disorders-treatment market include a pronounced shift towards digitalization, sustainability, and the integration of artificial intelligence in treatment protocols. Strategic alliances among key players are increasingly shaping the competitive landscape, fostering innovation and enhancing the reliability of supply chains. Looking ahead, competitive differentiation is likely to evolve from traditional price-based strategies to a focus on technological advancements and innovative treatment solutions, underscoring the importance of adaptability in a rapidly changing market. ## Recent News & Developments The South Korea Neuropsychiatric Disorders Treatment Market has been witnessing significant developments recently. Key players such as Hanmi Pharmaceutical and SK Biopharmaceuticals have made strides in advancing drug pipelines to address psychiatric conditions. The market is currently experiencing an uptick in investment, with companies like Samsung Biologics focusing on biologics for conditions like schizophrenia and depression. In terms of mergers and acquisitions, LG Chem announced a partnership with a biotech firm in August 2023 to expand its portfolio in neuropsychiatric treatments, enhancing its R&D capabilities. Additionally, Daewoong Pharmaceutical has been actively investing in innovative therapies, reflecting a broader trend of increased spending in the neuropsychiatric sector. The government's support for mental health initiatives further contributes to market growth, promoting accessibility and research funding. Over the past two years, there has been a noticeable increase in public awareness and reduced stigma regarding mental health, driving demand for products and services in this domain. As the market evolves, ongoing collaborations among key industry players are expected to create new opportunities for growth and innovation in South Korea's neuropsychiatric treatment landscape. ## Report Scope | MARKET SIZE 2024 | 3630.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 3999.9(USD Million) | | MARKET SIZE 2035 | 10550.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 10.19% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Johnson & Johnson (US), Pfizer (US), Eli Lilly and Company (US), AstraZeneca (GB), Bristol-Myers Squibb (US), Novartis (CH), Sanofi (FR), Roche (CH), Otsuka Pharmaceutical (JP) | | Segments Covered | Disorders, Treatment, End User | | Key Market Opportunities | Integration of digital therapeutics and personalized medicine in the neuropsychiatric disorders-treatment market. | | Key Market Dynamics | Rising demand for innovative therapies drives competition in the neuropsychiatric disorders-treatment market. | | Countries Covered | South Korea | ## Frequently Asked Questions **Q: What is the current valuation of the neuropsychiatric disorders-treatment market in South Korea?** A: The market was valued at $3630.0 Million in 2024. **Q: What is the projected market valuation for 2035?** A: The market is expected to reach $10550.0 Million by 2035. **Q: What is the expected CAGR for the South Korea neuropsychiatric disorders-treatment market during 2025 - 2035?** A: The expected CAGR is 10.19% during the forecast period. **Q: Which segments are included in the neuropsychiatric disorders category?** A: The segments include Degenerative Diseases, Neurotic Disorders, Psychosis, and Others. **Q: What were the valuations for the Neurotic Disorders segment in 2024?** A: The Neurotic Disorders segment was valued at $1080.0 Million in 2024. **Q: What is the projected valuation for the Drug Treatment segment by 2035?** A: The Drug Treatment segment is projected to reach $4200.0 Million by 2035. **Q: Who are the key players in the South Korea neuropsychiatric disorders-treatment market?** A: Key players include Johnson & Johnson, Pfizer, Eli Lilly and Company, and AstraZeneca. **Q: What is the valuation of the Hospitals segment in 2024?** A: The Hospitals segment was valued at $1450.0 Million in 2024. **Q: What is the expected growth for the Others segment in the Treatment category by 2035?** A: The Others segment in the Treatment category is expected to grow to $5300.0 Million by 2035. **Q: How does the valuation of the Psychosis segment compare to the Others segment in 2024?** A: In 2024, the Psychosis segment was valued at $726.0 Million, whereas the Others segment was valued at $1098.0 Million. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-korea-neuropsychiatric-disorders-treatment-market-45192*